Edgewise Therapeutics was founded in 2017 by Alan Russell, Ph.D., Peter Thompson, M.D. (Orbimed Advisors) and Badreddin Edris, Ph.D., (Springworks Inc.) and is pioneering the development of first-in-class medicines for the treatment of high morbidity musculoskeletal diseases. Skeletal muscle is the largest organ system in the human body, regulating both force production to enable muscle contraction, locomotion, and postural maintenance and the metabolism of glucose, fatty acid and amino acid. By modulating these processes in skeletal muscle, we create therapeutic agents that will reduce muscle damage, normalize muscle function, decrease mortality and profoundly benefit our patient's quality of life.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/17/19 | $50,000,000 | Series B |
CureDuchenne Ventures Deerfield Management Company, L.P. New Leaf Venture Partners Novo Holdings  OrbiMed Advisors US Venture Partners | undisclosed |
